---
title: "Evoke Pharma | 8-K: FY2025 Q2 Revenue Misses Estimate at USD 3.752 M"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/253022867.md"
published_at: "2025-08-14T11:09:19.000Z"
---

# Evoke Pharma | 8-K: FY2025 Q2 Revenue Misses Estimate at USD 3.752 M

Revenue: As of FY2025 Q2, the actual value is USD 3.752 M, missing the estimate of USD 3.796 M.

EPS: As of FY2025 Q2, the actual value is USD -0.62.

### Segment Revenue

-   Net product sales for Q2 2025 were $3.8 million, a 47% increase from $2.6 million in Q2 2024.

### Operational Metrics

-   Net loss for Q2 2025 was - $1.6 million, or - $0.62 per share, compared to - $1.3 million, or - $0.93 per share, in Q2 2024.
-   Selling, general, and administrative expenses increased to $5.1 million in Q2 2025 from $3.7 million in Q2 2024, primarily due to higher profit-sharing with EVERSANA and increased professional fees.
-   Total operating expenses for Q2 2025 were $5.3 million, up from $3.8 million in Q2 2024.

### Cash Flow

-   Net cash used in operating activities for the six months ended June 30, 2025, was - $1.6 million, compared to - $3.4 million for the same period in 2024.
-   Cash and cash equivalents as of June 30, 2025, were $12.1 million.

### Unique Metrics

-   New prescribers increased by 20% year-over-year, indicating growing clinical adoption of GIMOTI.
-   Refill rates remained steady at approximately 70%.

### Outlook / Guidance

-   Evoke Pharma confirms its full-year 2025 net product sales guidance of approximately $16 million, representing up to a 60% increase over 2024. This guidance reflects trends in prescription growth, refill rates, and expanded pharmacy access, while considering external factors such as macroeconomic conditions and supply chain constraints.

### Related Stocks

- [EVOK.US - Evoke Pharma](https://longbridge.com/en/quote/EVOK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Debt-laden William Hill UK owner Evoke explores sale after gambling tax hike | Evoke, owner of William Hill UK, is exploring a sale after UK tax hikes on online gaming and sports betting. The company | [Link](https://longbridge.com/en/news/269233994.md) |
| 10% Owner Roger M. Klein Sells Common Shares of Evoke Pharma Inc | Roger M. Klein, a 10% owner of Evoke Pharma Inc., has sold common shares of the company. The full filing is available th | [Link](https://longbridge.com/en/news/264933569.md) |
| Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025 | Evoke Pharma's Q3 2025 net product sales rose 61% year-over-year to $4.3 million. The company is set to be acquired by Q | [Link](https://longbridge.com/en/news/265721419.md) |
| Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical | Evoke Pharma has entered into a definitive agreement to be acquired by QOL Medical for $11.00 per share in cash, represe | [Link](https://longbridge.com/en/news/264214043.md) |
| 11:28 ET
			
			
				Shareholder Alert: The Ademi Firm investigates whether Evoke Pharma Inc. is obtaining a Fair Price for its Public Shareholders | The Ademi Firm is investigating Evoke Pharma Inc. (NASDAQ: EVOK) for potential breaches of fiduciary duty related to a r | [Link](https://longbridge.com/en/news/264262751.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.